In vivo anti-platelet properties of anipamil, a calcium channel blocker, in the rabbit.
The anti-platelet actions of anipamil, a new calcium channel blocker were studied in anesthetized rabbits using continuous on-line techniques to measure platelet count and platelet secretion by ATP release. Anipamil, at a dose of 0.5 mg/kg twice daily for three days, prior to challenge with collagen (100 micrograms/kg) or arachidonic acid (1.1 mg/kg), was without effect. However, 2 and 5 mg/kg of anipamil significantly retarded the decline in platelet count to both platelet activators, although anipamil failed to significantly diminish the hypotensive effect of these platelet activators, or significantly increase survival to arachidonic acid. Moreover, anipamil was without effect on the platelet effects of platelet activating factor (PAF). Thus, anipamil has the ability to partially inhibit the activation of platelets in vivo.
D000255:Adenosine Triphosphate / Q000097:blood; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D008297:Male; D014677:Pharmaceutical Vehicles; D010972:Platelet Activating Factor / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011437:Propylamines / Q000494:pharmacology*; D011817:Rabbits
D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D014677:Pharmaceutical Vehicles; D010972:Platelet Activating Factor; D011437:Propylamines; D000255:Adenosine Triphosphate; D003094:Collagen; C045313:anipamil